Clinical Trial Update: Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL [Phase 2, Phase 3]

View source ↗

Summary

This document provides an update on a Phase 2/Phase 3 trial evaluating intravenously administered autologous CD19 CAR-T cells for relapsed or refractory B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Autologous CD19 CAR-T cell therapy (CD19-directed CAR-T cell)

Snippet

Sponsor: National University of Malaysia | Conditions: Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia | Phase 2, Phase 3 | Status: RECRUITING